198 related articles for article (PubMed ID: 22543585)
21. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
22. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells.
Schaefer KL; Takahashi H; Morales VM; Harris G; Barton S; Osawa E; Nakajima A; Saubermann LJ
Int J Cancer; 2007 Feb; 120(3):702-13. PubMed ID: 17096328
[TBL] [Abstract][Full Text] [Related]
23. Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells.
Wang ZF; Li J; Ma C; Huang C; Li ZQ
Biochem Pharmacol; 2020 Jan; 171():113674. PubMed ID: 31634455
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.
Polikandriotis JA; Mazzella LJ; Rupnow HL; Hart CM
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1810-6. PubMed ID: 16020752
[TBL] [Abstract][Full Text] [Related]
25. Interplay between SOX9, β-catenin and PPARγ activation in colorectal cancer.
Panza A; Pazienza V; Ripoli M; Benegiamo G; Gentile A; Valvano MR; Augello B; Merla G; Prattichizzo C; Tavano F; Ranieri E; di Sebastiano P; Vinciguerra M; Andriulli A; Mazzoccoli G; Piepoli A
Biochim Biophys Acta; 2013 Aug; 1833(8):1853-65. PubMed ID: 23583560
[TBL] [Abstract][Full Text] [Related]
26. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.
Zhang W; Wu N; Li Z; Wang L; Jin J; Zha XL
Cancer Biol Ther; 2006 Aug; 5(8):1008-14. PubMed ID: 16775433
[TBL] [Abstract][Full Text] [Related]
27. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.
Seargent JM; Yates EA; Gill JH
Br J Pharmacol; 2004 Dec; 143(8):933-7. PubMed ID: 15533890
[TBL] [Abstract][Full Text] [Related]
28. Curcumin cytotoxicity is enhanced by PTEN disruption in colorectal cancer cells.
Chen L; Li WF; Wang HX; Zhao HN; Tang JJ; Wu CJ; Lu LT; Liao WQ; Lu XC
World J Gastroenterol; 2013 Oct; 19(40):6814-24. PubMed ID: 24187456
[TBL] [Abstract][Full Text] [Related]
29. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN.
Lee KS; Park SJ; Hwang PH; Yi HK; Song CH; Chai OH; Kim JS; Lee MK; Lee YC
FASEB J; 2005 Jun; 19(8):1033-5. PubMed ID: 15788448
[TBL] [Abstract][Full Text] [Related]
30. The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer.
Chu R; van Hasselt A; Vlantis AC; Ng EK; Liu SY; Fan MD; Ng SK; Chan AB; Liu Z; Li XY; Chen GG
Cancer; 2014 Jan; 120(1):142-53. PubMed ID: 24114184
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor γ ligands retard cultured vascular smooth muscle cells calcification induced by high glucose.
Zhou YB; Zhang J; Peng DQ; Chang JR; Cai Y; Yu YR; Jia MZ; Wu W; Guan YF; Tang CS; Qi YF
Cell Biochem Biophys; 2013 Jul; 66(3):421-9. PubMed ID: 23274912
[TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma.
Zhang YQ; Tang XQ; Sun L; Dong L; Qin Y; Liu HQ; Xia H; Cao JG
World J Gastroenterol; 2007 Mar; 13(10):1534-40. PubMed ID: 17461445
[TBL] [Abstract][Full Text] [Related]
33. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
34. Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone.
Teresi RE; Shaiu CW; Chen CS; Chatterjee VK; Waite KA; Eng C
Int J Cancer; 2006 May; 118(10):2390-8. PubMed ID: 16425225
[TBL] [Abstract][Full Text] [Related]
35. A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis.
Aires V; Brassart B; Carlier A; Scagliarini A; Mandard S; Limagne E; Solary E; Martiny L; Tarpin M; Delmas D
Mol Nutr Food Res; 2014 Sep; 58(9):1785-94. PubMed ID: 24975132
[TBL] [Abstract][Full Text] [Related]
36. PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells.
Toaldo C; Pizzimenti S; Cerbone A; Pettazzoni P; Menegatti E; Daniela B; Minelli R; Giglioni B; Dianzani MU; Ferretti C; Barrera G
J Cell Mol Med; 2010 Jun; 14(6A):1347-57. PubMed ID: 19912441
[TBL] [Abstract][Full Text] [Related]
37. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma.
Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH
Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131
[TBL] [Abstract][Full Text] [Related]
39. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
40. Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model.
Wu W; Celestino J; Milam MR; Schmeler KM; Broaddus RR; Ellenson LH; Lu KH
Int J Gynecol Cancer; 2008; 18(2):329-38. PubMed ID: 18334011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
